Literature DB >> 22430209

PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.

R L Ross1, J M Askham, M A Knowles.   

Abstract

Although activating mutations of PIK3CA are frequent in urothelial carcinoma (UC), no information is available on their specific effects in urothelial cells or the basis for the observed mutation spectrum, which has a large excess of helical domain mutations. We investigated the phenotypic and signaling consequences of hotspot and UC-specific rare PIK3CA mutations in immortalized normal human urothelial cells (NHUC) and mouse fibroblasts (NIH3T3). Our results indicate that in NHUC, rare mutant forms and all three hotspot mutant forms of PIK3CA can activate the PI3K/AKT pathway. The relative frequency at which helical domain and kinase domain mutations are found in UC is related to their potency in inducing signaling downstream of AKT and to the phenotypic effects induced in this cell type (E545K>E542K>H1047R). Helical domain mutations E542K and E545K conferred a significant proliferative advantage at confluence and under conditions of nutrient depletion, and increased cellular resistance to anoikis. Both helical and kinase domain mutants induced increased NHUC cell motility and migration towards a chemoattractant, though no significant differences were found between the mutant forms. In NIH3T3 cells, the kinase domain mutant H1047R induced high levels of AKT activation, but helical domain mutants were significantly less potent and this was reflected in their relative abilities to confer anchorage-independent growth. Our findings indicate that the effects of mutant PIK3CA are both cell type- and mutation-specific. Helical domain mutations in PIK3CA may confer a selective advantage in the urothelium in vivo by overcoming normal contact-mediated inhibitory signals and allowing proliferation in nutrient-limiting conditions. Mutant forms of PIK3CA may also stimulate intraepithelial cell movement, which could contribute to spread of cells within the urothelium.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430209     DOI: 10.1038/onc.2012.87

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Mutation of chromatin regulators and focal hotspot alterations characterize human papillomavirus-positive oropharyngeal squamous cell carcinoma.

Authors:  Sunny Haft; Shuling Ren; Guorong Xu; Adam Mark; Kathleen Fisch; Theresa W Guo; Zubair Khan; John Pang; Mizuo Ando; Chao Liu; Akihiro Sakai; Takahito Fukusumi; Joseph A Califano
Journal:  Cancer       Date:  2019-04-01       Impact factor: 6.860

Review 2.  The route to personalized medicine in bladder cancer: where do we stand?

Authors:  Francesco Massari; Chiara Ciccarese; Matteo Santoni; Matteo Brunelli; Alessandro Conti; Alessandra Modena; Rodolfo Montironi; Daniele Santini; Liang Cheng; Guido Martignoni; Stefano Cascinu; Giampaolo Tortora
Journal:  Target Oncol       Date:  2015-01-30       Impact factor: 4.493

Review 3.  Novel molecular targets for urothelial carcinoma.

Authors:  Bishoy M Faltas; Beerinder S Karir; Scott T Tagawa; Jonathan E Rosenberg
Journal:  Expert Opin Ther Targets       Date:  2015-01-30       Impact factor: 6.902

4.  Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

Authors:  Filip Janku; David S Hong; Siqing Fu; Sarina A Piha-Paul; Aung Naing; Gerald S Falchook; Apostolia M Tsimberidou; Vanda M Stepanek; Stacy L Moulder; J Jack Lee; Rajyalakshmi Luthra; Ralph G Zinner; Russell R Broaddus; Jennifer J Wheler; Razelle Kurzrock
Journal:  Cell Rep       Date:  2014-01-16       Impact factor: 9.423

Review 5.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

6.  Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.

Authors:  Ayesha Joshi; Christopher Miller; Suzanne J Baker; Lora H Ellenson
Journal:  Am J Pathol       Date:  2015-02-16       Impact factor: 4.307

7.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

8.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Authors:  Filip Janku; Jennifer J Wheler; Aung Naing; Gerald S Falchook; David S Hong; Vanda M Stepanek; Siqing Fu; Sarina A Piha-Paul; J Jack Lee; Rajyalakshmi Luthra; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Cancer Res       Date:  2012-10-12       Impact factor: 12.701

9.  Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.

Authors:  Zheqi Li; Kevin M Levine; Amir Bahreini; Peilu Wang; David Chu; Ben Ho Park; Steffi Oesterreich; Adrian V Lee
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

Review 10.  [YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?].

Authors:  P S Holm; M Retz; J E Gschwend; R Nawroth
Journal:  Urologe A       Date:  2016-03       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.